Sivakumar murugesan
Hospitals Project , Patient Safety and Quality Improvement Consultant
Medpoint Provides NABH Accreditation Consultancy Services to Healthcare Organisations.As part of our service here we publish drug recall procedure guidelines for your reference.
Introduction:
Recall is an action taken to withdraw/remove the drugs from distribution or use including corrective action for which
deficiencies are reported in quality, efficacy or safety. The defective products related to quality
includes Not of Standard Quality, Adulterated or Spurious drugs. Safety
and efficacy related recalls include serious adverse reactions and death. Recalls also include drugs
prohibited under the Provisions of Drugs & Cosmetics Act and also
those products for which product licenses are suspended/cancelled.
Rapid
Alert System is to transmit only those alerts whose urgency and seriousness
cannot permit any delay in
transmission. Assessment must be made of the seriousness of the defect, its potential for causing harm to the patient or harm to animals (in case of veterinary product),
consumers, operators and the environment.
Background:
In the Drugs & Cosmetics Act & Rules, there are
references for product recalls, complaint and
adverse reactions in Para 27 & 28 of Schedule M and also conditions of
license for defective product
recall in Rule 74(j) and Rule 78(i), but effective
and uniform recall
procedure, with time lines at every level of supply chain is required
and at present auditing and
accountability is not in place. This has been observed in instances where drugs
declared as not of standard
quality by Government Analyst, incidents where serious adverse
effects or death have been
reported, in case of banned drugs under Section 26 A, defects where in voluntarily the manufacturer withdraws drugs from the market
etc.
Scope:
These guidelines is applicable to all quality defective
product reports and to all reported incidents of safety and efficacy received for
all drugs including vaccines &
biological. These guidelines are expected to be followed
by licensees (manufacturers, importers, stockists,
distributors, retailers) and the recall could be voluntary or statutory. The
procedure may also be used by Drugs
Control Authorities of Central or State when urgent action is required
to protect public
or animal health.
These guidelines would help in adopting to stepwise procedures to be followed in recall strategy
and also help in recall
evaluation at every
level and achieve compliance within the time frame.
Definitions:
Recall: Removal or correction of marketed products
for the reasons relating to deficiencies
in quality, safety or efficacy, including labeling considered to be in violation
of the laws.
Batch Recall:
Process for removal of
selected batch/es of a product which are found to be defective and pose
health risk to the consumers if left in the market.
Batch (Lot): A specific
quantity of material produced in a process or series of processes so that
it is expected to be homogeneous within specified limits.
Customer: Any person, firm or party buying/receiving goods from the company for storage,
distribution and sale.
Voluntary Recall: A recall initiated by the licensee
(in case of loan licensee jointly the contract
giver and contract acceptor) as a
result of abnormal observation in any product
quality during periodic review (Internal / External) or investigation of
a market complaint or any other failures.
Statutory Recall: A recall directed by Drug Control Authorities after notifying that product is considered to be in violation
of the laws. e.g., Declared as Not of
Standard Quality by Government
Analyst and Banned under 26A of Drugs and Cosmetics
Act 1940 (as amended from time to time)and as well as contravention of Rule 104-A of Drugs & Cosmetics Rules1945( as amended
from time to time)
Recall Classification:
Recall classification is a numerical designation, I, II, or
III, that is assigned to a particular
product recall that indicates the relative degree of health hazard by country regulatory authorities.
In case of not of standard quality drugs, the recommendations of 39th DCC guidelines
for category A,B and C may be accordingly adopted for Class I, Class II and Class III until further recommendations if
any. All banned Drugs & Products for which
license is suspended, cancelled which are in circulation in market shall
also be considered to be Class I recalls
only.
Class I is a situation in
which there is a reasonable probability that the use of, or exposure to, a defective product will
cause serious adverse health consequences or death and as well as banned
under 26A of Drugs and Cosmetics Act
1940.
Class II is situation in
which the use of, or exposure to, a defective product may cause temporary adverse health
consequences or where the probability of serious adverse health consequences
is remote.
Class III is a situation in
which the use of, or exposure to, a defective product is not likely to cause any adverse health consequences.
Recall Procedures:
Any batch of a product
not meeting the defined quality standards has to be recalled
from the market. Recall can be of two types; Voluntary Recall and Statutory Recall.
Voluntary Recall:
Voluntary recall can be triggered by any incident
that affects the quality, safety
and efficacy of the batch/product in question such as
1. If the batch or
batches are found to be not complying with the regulatory specifications during
the post marketing stability study
2.
If the batch is found to be defective
during investigation of market complaint.
3. During any failure
investigation, if it is observed that the failure under investigation might have adverse
quality impact on already released
batch (e.g. possibility of contamination, mix-up, degradation etc).
4. If any unusual
observation is noted during visual inspection of retention samples which indicate an impact on quality of the product
after investigation.
5. If the post
marketing surveillance reports /pharmacovigilance reports indicates that there is
serious safety risk associated with
the product.
Statutory Recall:
Statutory recall can be triggered in response to the direction
or mandate by the Drug Regulatory Authorities (Central/State) in one or more of the situations
as follows :
1. To recall the drug product/batch, considered to be in violation of the laws,
it administers such as not of standard
quality etc.
2.
To recall
the banned drugs.
3.
Labeling and / or Promotional materials, that are considered to be in violation of law.
4.
Product, violation Rule 106 (Diseases under Schedule J)
Levels of
Recall:
The level (or depth) of recall of a product/batch shall be determined based on recall
classification and level to which distribution has taken place.
There are three levels
of recall such as consumer/user, retail and wholesale.
Consumer or User Level: which may vary
with product, including any intermediate wholesale
or retail level. Consumer or user may include individual consumers, patients, physicians and hospitals.
Retail Level:- recall to the level immediately preceding consumer or user level. It includes
retail groceries, pharmacies, hospital pharmacies, dispensing physician, institutions such as
clinics and nursing homes,
etc.
Wholesale Level: all distribution levels
between the manufacturer and retailer.
All Class I recalls shall be executed to the levels of
Wholesale/Distributors, retail, and
consumer. In such cases, public announcements shall be made using
print/electronic media aids viz. Newspapers, Television, Radio
etc.
All Class II recalls
shall be executed up to the levels of wholesale
and retail. All Class III recalls
shall be executed up to the levels of wholesale.
Time Lines for Effective Recall
System & Rapid Alert:
Based on the category of risks involved, a time line of
within 24 hours up to a maximum of 72
hours for Class I recall, for class II recall up to a maximum of 10 days and for Class III recall up
to a maximum of 30 days is allowed.
The time line for initiation of recall procedure to
commence from the receipt of information
as notified by the concerned State/ Central Drugs Control Department under statutory
recall or voluntary recall by
the manufacturer on its own.
The recall has to be initiated immediately without any
prejudice of the outcome of Section
25(3) and Section 25(4) of the Drugs & Cosmetics Act 1940 for adducing the evidence. The time line for stopping
sale/distribution of defective product under Class I shall be ensured within 24 hours and the physical recall being
completed within 72 hours. The Class II and Class III recalls shall be ensured upto 10 and upto 30 days respectively.
Read Also
Fire Safety Guidelines for New and Existing Hospitals and Healthcare Facility
Effective Administration of LASA Drugs
Procedure for Rapid Alert & Recall System:
As soon as the product/batch(es) to be recalled
is/are identified, licensee
or representative of licensee
or QA in charge shall review the
information related to the defective product/batch(es) and decide about recall as per the procedure established.
The decision on recall of the defective
product/batch shall be made within 24 Hours
up to maximum of 72
Hours for Class I recall upon receipt of the intimation.
Within 24 Hours of the decision taken for the recall of the
product/batch(es) the communication
shall be sent stating the severity of the defect, using the fastest mode of communication which may include email,
telephone, fax, SMS etc to the entire supply
chain.
The licensee/representative of licensee where the product
is marketed shall inform the concerned
regulatory authorities where the product
batch(es) in question
was distributed immediately
after the decision of recall has been taken. Further actions on recall
will be undertaken according to class of recall.
Recall classification of the product/batch in question
shall be done based on the risk assessment in line with the
recall classification as given in definition.
It shall be the responsibility of the manufacturer and marketing company
to inform up to
retail level on the reason of recall
in his freeze stock notice.
It shall be the responsibility of distributor/marketing
company/ retailer to inform the stock position of product being recalled to his immediate supplier or manufacturer and also
his area Drugs Inspector.
The recall notice received, the stock at that time, the
procedure for freezing the stock and returned back records shall be maintained by the distributor/retailer and shall be made available for verification by
area Drugs Inspector who shall verify and report on its timely freezing and return.
Stepwise Recall Procedure:
The licensee/representative of licensee/Quality
Head in charge shall enter the details in the ‘Recall Log’ and assign a
unique recall reference number representing the serial number for a particular year in which the recall has been initiated.
The licensee/representative of licensee/ Quality Head in
charge shall inform the Distributor/Marketing
Company with fastest mode of
communication which may include email,
telephone, fax, sms etc. to stop further distribution of the batch(es) in the
stock and call back the stock available with the distributors, retailers etc, depending
on the seriousness of the defect.
“Product/batch Recall Notice”
shall be filled
and sent by licensee/representative of licensee/
Quality Head in charge to
Distributor / Marketing Company.
Distributor / Marketing Company shall immediately check the
distribution record to identify the
Customers and Warehouse, depots where
the subject product / batches have been distributed and forward the
copies of the Recall Notice to them for further necessary action.
The Head of depot(s) shall fill ‘Recall
Notification’ and forward
it to all distributors to return all unsold stock.
Simultaneously, the Heads
of respective depots
/ware houses
shall block the available stock.
The Distribution Head shall ensure
the blockage of stock for further sale by reviewing
the record.
The distributor(s) shall send the “Return Feedback” along
with goods (if any) to the depots.
All the returned stocks shall be further forwarded to the ware houses.
The Head of ware houses shall send a periodical
report to licensee/representative of licensee /QA head of the stock
available with them and the returns received from depots.
Head of ware house shall reconcile the stocks of the
recalled materials against the total
quantity of distributed material and fill the “Summary Report of Product /
Batch Recall”. The copy shall be
forwarded to licensee/representative of licensee/QA in charge for review and necessary action.
The recall of the product/batch shall be completed
depending on the class of recall within the stipulated
time.
Follow-Up Action of Recalled Goods:
The follow-up action consists of a check on the
effectiveness of the recall, an investigation
of the reason for the recall and remedial action taken to prevent a recurrence of the defect.
The licensee/representative of licensee/QA Head shall monitor
the recall process of product/batch to determine whether
the recall is progressing satisfactorily.
The stocks of recalled goods shall be placed under “Quarantine” and stored separately under lock and key
in a secure area until further decision.
Wherever required,
QA Head of the manufacturing site shall perform
the physical inspection of recalled goods and collect
sample from recalled goods for investigation to establish the root cause of the product quality defect.
The
investigation of the recalled batch(es) shall be conducted as per the SOP of
the licensee, on “Investigation of
Non-conformities” to identify the root cause of the failure and initiate corrective and preventive actions
Impact assessment shall be conducted on other batches of
the concerned product and further extended to batch(es) of other product(s), wherever applicable.
If the cause of recall is established to be quality issue
associated with any of the raw
material used, then the traceability of that material shall be established in
all the product/batches.
Alternatively execute the transaction through records to
identify the batches / products in which the identified material has been
used.
Monitoring the relevant data i.e. Material,
Plant and Batch Number in respective
fields.
Identify the raw material
traceability in different formulations and its
functions.
List all raw materials along with batch numbers and the
respective quantities used in those
batches.
List all the products along with batch numbers and the respective
quantities used in those batches.
Calculate the total quantity by adding individual quantities used in various products
/ batches.
Monitoring of the material movement to get the complete
overview of stock for that particular material in the plant and extract the information about total quantity
received and the balance
quantity.
The balance stock, if any shall
be verified against
the actual physical
stock available. QA shall
block the remaining available stock.
All material shall be accounted for after the reconciliation
The decision to recall, if necessary, any of the impacted batches shall be
made after product quality assessment.
Based on conclusion of
the investigation findings, the QA Head / representative of licensee
shall direct the Distributor / Marketing Company for appropriate disposition of the batch(es)
of the recalled goods as per the regulations.
MOCK RECALL:
Mock recall shall be carried out for at least one batch of
any product, dispatched for sale where maximum
distributors are involved,
to test the effectiveness of the arrangements of recall. Effectiveness of recall procedure
can also be checked by ‘evaluation of a real recall’.
During mock recall traceability shall be performed for at
least, one of the raw material used in
the batches identified for mock recall.
Mock Recall shall be
performed at least once for the
longest distribution chain and whenever there
is a change in distributor/marketing company.
Records of such mock recall should be maintained by the QA Head of the company.
References:
1. The Drugs & Cosmetics Act 1940 &
Rules 1945.
2.
The WHO TRS for GMP Guidelines.
3. Work Shop on Recall & Rapid Alert System, held at New Delhi Office from 27th to 30th August
2012 organized by CDSCO in collaboration with WHO.
4. USFDA documents on recall.
5. The Guidelines on Recall & Rapid Alert System for Drugs including Biologicals and Vaccines.

